BNTX [NASD]
BioNTech SE
Index- P/E3.05 EPS (ttm)43.28 Insider Own64.01% Shs Outstand240.23M Perf Week2.81%
Market Cap32.63B Forward P/E8.98 EPS next Y14.71 Insider Trans0.00% Shs Float215.11M Perf Month-3.30%
Income10.95B PEG- EPS next Q8.84 Inst Own17.00% Short Float / Ratio0.91% / 2.84 Perf Quarter-23.51%
Sales19.69B P/S1.66 EPS this Y-8.00% Inst Trans11.87% Short Interest1.96M Perf Half Y0.62%
Book/sh81.08 P/B1.63 EPS next Y-60.40% ROA51.60% Target Price212.61 Perf Year-22.13%
Cash/sh57.65 P/C2.29 EPS next 5Y- ROE65.50% 52W Range117.08 - 188.99 Perf YTD-10.76%
Dividend- P/FCF2.50 EPS past 5Y- ROI86.30% 52W High-29.07% Beta0.24
Dividend %- Quick Ratio5.30 Sales past 5Y- Gross Margin81.70% 52W Low14.49% ATR3.50
Employees3082 Current Ratio5.40 Sales Q/Q-43.10% Oper. Margin75.70% RSI (14)50.82 Volatility2.34% 2.64%
OptionableYes Debt/Eq0.01 EPS Q/Q-43.50% Profit Margin55.60% Rel Volume0.64 Prev Close132.08
ShortableYes LT Debt/Eq0.01 EarningsMar 27 BMO Payout0.00% Avg Volume691.30K Price134.05
Recom2.20 SMA202.53% SMA50-3.30% SMA200-9.70% Volume68,499 Change1.49%
Dec-15-22Upgrade BofA Securities Neutral → Buy $239
Aug-17-22Initiated Cowen Market Perform $177
Jul-13-22Upgrade SVB Leerink Mkt Perform → Outperform
Jul-06-22Resumed Canaccord Genuity Buy $192
Feb-01-22Upgrade Redburn Sell → Neutral
Dec-16-21Initiated Morgan Stanley Equal-Weight $294
Nov-10-21Upgrade H.C. Wainwright Neutral → Buy $360
Oct-22-21Initiated Deutsche Bank Hold $250
Oct-07-21Initiated Jefferies Hold $230
Aug-11-21Upgrade Bryan Garnier Neutral → Buy $451
Show Previous Ratings
Mar-21-23 03:02AM
Mar-20-23 06:00PM
08:35AM
07:45AM
Mar-19-23 12:44PM
10:00AM Loading…
10:00AM
Mar-18-23 03:12AM
Mar-16-23 11:16PM
05:42AM
Mar-15-23 02:38PM
10:21AM
08:39AM
Mar-14-23 07:01PM
04:26AM
Mar-13-23 06:00PM
07:45AM Loading…
07:45AM
07:00AM
Mar-10-23 10:29AM
08:00AM
Mar-09-23 06:00AM
Mar-06-23 05:50PM
Mar-04-23 08:19AM
Mar-03-23 09:07AM
Mar-01-23 10:31AM
08:00AM
07:11AM
Feb-27-23 05:50PM
Feb-24-23 05:06PM
12:03PM
09:43AM
03:51PM Loading…
Feb-22-23 03:51PM
Feb-21-23 05:50PM
Feb-19-23 07:59AM
Feb-18-23 08:00AM
Feb-17-23 10:17AM
Feb-16-23 11:05AM
Feb-14-23 05:50PM
04:33PM
06:00AM
Feb-10-23 07:00AM
Feb-08-23 05:50PM
Feb-06-23 06:15AM
06:00AM
Feb-04-23 08:00AM
Feb-03-23 11:34AM
10:52AM
08:32AM
Feb-02-23 05:50PM
02:19PM
09:25AM
08:38AM
06:45AM
06:45AM
05:02AM
Jan-30-23 05:00AM
Jan-27-23 04:41PM
04:08PM
09:13AM
Jan-26-23 07:31AM
Jan-25-23 10:37AM
Jan-23-23 08:09AM
Jan-20-23 09:06AM
Jan-19-23 10:17AM
08:03AM
Jan-18-23 01:14PM
Jan-17-23 01:56PM
10:34AM
Jan-13-23 06:15PM
04:22PM
Jan-12-23 11:28AM
Jan-11-23 12:16PM
Jan-10-23 11:55AM
09:33AM
09:22AM
07:53AM
07:15AM
04:59AM
Jan-09-23 01:40PM
12:50PM
05:13AM
Jan-08-23 08:00AM
Jan-06-23 03:43AM
Jan-05-23 07:01PM
07:01PM
04:15AM
Jan-04-23 09:51AM
09:00AM
Jan-02-23 07:00AM
Dec-30-22 06:50PM
Dec-29-22 09:40AM
03:01AM
Dec-28-22 09:13AM
06:45AM
06:20AM
Dec-27-22 06:50PM
Dec-23-22 05:24AM
04:42AM
03:00AM
02:33AM
Dec-22-22 11:10PM
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc. and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.